Wall Street Upgrades Rezolute After Strong Phase 3 Trial Results in Tumor Hyperinsulinism

Rezolute’s drug showed strong Phase 3 results, reducing IV glucose needs in rare tumor HI. Analysts raised targets and turned bullish.